A randomized study to evaluate efficacy of nalbuphine as an adjuvant to ropivacaine for ultrasound guided block of lower limb for surgeries of diabetic foot

Efficacy of nalbuphine as an adjuvant to ropivacaine for ultrasound guided combined adductor canal and popliteal sciatic block in high risk patients undergoing elective diabetic foot wound debridement a prospective randomised double blind study - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083425

Enrollment

100

Registered

2025-03-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group B Nalbuphine: Nalbuphine 5mg with 9ml of 0.375% Ropivacaine for Adductor canal block 14ml OF 0.375% Ropivacaine with 5mg Nalbuphine for Popliteal sciatic block Control Interventio

Eligibility

Inclusion criteria

Inclusion criteria: ASA GRADE 3 AND 4 DIABETIC PATIENTS POSTED FOR WOUND DEBRIDEMENT

Exclusion criteria

Exclusion criteria: PATIENTS ALLERGIC TO STUDY DRUGS PATIENTS ON MEDICATIONS FOR CHRONIC PAIN NEUROLOGIC DEFICITS CONTRAINDICATION TO PERIPHERAL NERVE BLOCKS ON ANTICOAGULANT TREATMENT PREGNANT PATIENTS

Design outcomes

Primary

Measure	Time frame
To compare the duration of AnalgesiaTimepoint: Time of first analgesic request Total rescue analgesics in 24hrs Total duration of analgesia	—

Secondary

Measure	Time frame
To compare the onset of sensorimotor blockade To compare the adverse effects in both groupsTimepoint: sensorimotor blockade assessed at baseline 15mins 1 2 4 6 12 24hours	—

Countries

India

Contacts

Public ContactK Sree lekha

Government general hospital Kadapa

saya_knl@yahoo.com94907 14590

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026